Exhibit 10.1

SIXTH AMENDMENT TO AMENDED AND RESTATED
CREDIT AND SECURITY AGREEMENT

        This Amendment, dated as of June 27, 2005 is made by and between MEDTOX
SCIENTIFIC, INC., a Delaware corporation (“Scientific”), MEDTOX LABORATORIES,
INC., a Delaware corporation (“Laboratories”), MEDTOX DIAGNOSTICS, INC., a
Delaware corporation (“Diagnostics”), and CONSOLIDATED MEDICAL SERVICES, INC., a
Delaware corporation (“Consolidated”, and together with Scientific, Laboratories
and Diagnostics, collectively, the “Borrowers”, and each a “Borrower”), and
WELLS FARGO BUSINESS CREDIT, INC., a Minnesota corporation formerly known as
Norwest Business Credit, Inc. (the “Lender”).

Recitals

        The Borrowers and the Lender are parties to an Amended and Restated
Credit and Security Agreement dated as of May 7, 2001 but effective as of March
31, 2001, as amended by a First Amendment to Amended and Restated Credit and
Security Agreement dated as of October 24, 2001, a Second Amendment to Amended
and Restated Credit and Security Agreement dated as of May 10, 2002, a Third
Amendment to Amended and Restated Credit and Security Agreement dated as of
August 15, 2003, a Fourth Amendment to Amended and Restated Credit and Security
Agreement dated as of March 5, 2004, and a Fifth Amendment to Amended and
Restated Credit and Security Agreement dated as of September 27, 2004 (as so
amended, the “Credit Agreement”). Capitalized terms used in these recitals have
the meanings given to them in the Credit Agreement unless otherwise specified.

        The Borrowers have requested that certain amendments be made to the
Credit Agreement, which the Lender is willing to make pursuant to the terms and
conditions set forth herein.

        NOW, THEREFORE, in consideration of the premises and of the mutual
covenants and agreements herein contained, it is agreed as follows:

    1.        Defined Terms. Capitalized terms used in this Amendment which are
defined in the Credit Agreement shall have the same meanings as defined therein,
unless otherwise defined herein. In addition, Section 1.1 of the Credit
Agreement is amended by adding or amending, as the case may be, the following
definitions:

 

        “'2000 Capex Advances’ means the Advances made to the Borrowers
evidenced by the 2000 CapEx Note.”

 

        “'2001 Capex Advances’ means the Advances made to the Borrowers
evidenced by the 2001 CapEx Note.”

--------------------------------------------------------------------------------

 

        “'2004 Capex Advances’ means the Advances made to the Borrowers
evidenced by the 2004 CapEx Note.”

 

        “'2005 Capex Advances’ has the meaning given in Section 2.8.”

 

        “'2005 Capex Note’ means the promissory note of the Borrowers, dated as
of June 27, 2005, payable to the order of the Lender in the original principal
amount $1,500,000 and in substantially the form of Exhibit A to the Sixth
Amendment or any note or notes issued in substitution therefor, as the same may
hereafter be amended, supplemented or restated from time to time.”

 

        ‘Maturity Date’ means April 1, 2007.”

 

        “‘Term Advance’ means a 2000 Capex Advance, a 2000 Term Advance, a 2001
Capex Advance, a 2004 Capex Advance or a 2005 Capex Advance and “Term Advances”
means collectively, the 2000 Capex Advances, the 2000 Term Advances, the 2001
Capex Advances, the 2004 Capex Advances and the 2005 Capex Advances.”

    2.        Capex Advances. Section 2.1(b) is amended in its entirety to read
as follows:

    “(b)        Capex Advances. As of the Sixth Amendment Effective Date, the
outstanding total principal balance of the 2000 Capex Note, 2001 Capex Note, and
2004 CapEx Note was $721,715.40, with interest paid through May 31, 2005. No
Borrower has any claim, defense or offset to enforcement of the 2000 Capex Note,
the 2001 CapEx Note or the 2004 CapEx Note.”

    3.        2005 Capex Advances. Sections 2.8 and 2.9 of the Credit Agreement
are amended to read as follows:

 

        “Section 2.8 2005 Capex Advances. The Lender may, in its sole
discretion, make advances to the Borrowers from time to time, from the Sixth
Amendment Effective Date through April 1, 2006, in an aggregate amount not to
exceed the lesser of $1,500,000 or eighty percent (80%) of the purchase price
(less insurance, freight, delivery, interest, taxes, installation, licenses or
any similar costs or expenses, and less any discounts, rebates, refunds or other
reductions in price) of new Equipment other than leasehold improvements, office
and recordkeeping equipment or furniture (the “2005 Capex Advances”). The
Borrowers’ obligation to pay the 2005 Capex Advances shall be evidenced by the
2005 Capex Note and shall be secured by the Collateral as provided in
Article III. The 2005 Capex Advances are term advances. Any 2005 Capex Advances
that are prepaid may not be reborrowed.

- 2 -

Medtox - Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------

 

        Section 2.9 Requests for 2005 Capex Advances. The Borrowers shall comply
with the following procedures when requesting 2005 Capex Advances:

 

        (a)        Requests for a 2005 Capex Advance shall be made on an
individual Borrower basis and shall be made in writing, by a person authorized
under Section 2.3, specifying the amount of the 2005 Capex Advance, and the date
it is to be made, which shall be at least five (5) Banking Days after the date
of the request. The Borrowers shall be obligated to repay all 2005 Capex
Advances notwithstanding the fact that the Person requesting the same was not in
fact authorized to do so. Any request for a 2005 Capex Advance shall be deemed
to be a representation by the Borrowers that the conditions set forth in Section
4.2 have been met as of the time of the request.

 

        (b)        Each request shall be accompanied by (i) the actual invoice
and purchase order for the newly acquired Equipment, (ii) a description of such
Equipment, (iii) evidence of (A) delivery of such Equipment to the applicable
Borrower and its acceptance by the applicable Borrower, (B) title to such
Equipment in the name of the applicable Borrower, (C) payment therefor or a
letter from the applicable Borrower directing the Lender to disburse the 2005
Capex Advance proceeds to the Equipment vendor directly, (D) the Lender’s first
priority security interest in such Equipment, (E) insurance on such Equipment in
form and substance acceptable to the Lender; and (iv) such other documentation
or information as the Lender may require.

 

        (c)        Upon the Lender’s determination to make a 2005 Capex Advance,
the Lender shall disburse the amount of the 2005 Capex Advance by crediting the
same to the demand deposit account of the applicable Borrower, as specified in
Section 2.2, unless the applicable Borrower and the Lender shall agree in
writing to another manner of disbursement.”

    4.        Payment on Term Notes. The following new subsection (e) is hereby
added to Section 2.10 of the Credit Agreement immediately following subsection
(d):

        “(e) 2005 Capex Note.

 

    (i)     The amount of each 2005 Capex Advance shall be due and payable
beginning on the first day of the first month after the date on which that 2005
Capex Advance is made, and continuing on the first day of each month thereafter,
in substantially equal monthly installments in an amount sufficient to fully
amortize the principal balance of that 2005 Capex Advance in 48 equal monthly
installments; the principal amount to be paid each month on the 2005 Capex Note
shall be the sum of such monthly installments; and

- 3 -

Medtox - Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------

    (ii)        On the Termination Date, the entire unpaid principal balance of
the 2005 Capex Note, and all unpaid interest accrued thereon, shall be due and
payable in full.”

    5.        Audit Fees. Section 2.11(a) of the Credit Agreement is amended in
its entirety to read as follows:

    “(a)        Audit Fees. The Borrowers shall pay the Lender, on demand, audit
fees in connection with any audits or inspections conducted by the Lender of any
Collateral or the Borrowers’ operations or business at the rates established
from time to time by the Lender as its audit fees (which fees are currently $800
per day per collateral examiner), together with all actual out-of-pocket costs
and expenses incurred in conducting any such audit or inspection. Except during
a Default Period, such audits shall be conducted no more frequently than on a
semi-annual basis.”

    6.        Termination and Prepayment Fees. Section 2.17 is amended by
amended subsections (a) and (b) to read as follows:

    “(a)        Termination Fees. If the Credit Facility is terminated for any
reason as of a date other than the Maturity Date, the Borrowers shall pay the
Lender a fee equal to one quarter of one percent (0.25%) of the Maximum Line.

    (b)        Prepayment Fees. If the Term Advances are prepaid for any reason,
the Borrowers shall pay to the Lender a fee equal to one quarter of one percent
(0.25%) of the amount prepaid.”

    7.        Financial Covenants. Sections 6.13, 6.14 and 7.10 are each amended
in their entirety to read as follows:

 

        “Section 6.13 Minimum Debt Service Coverage Ratio. The Borrowers will
maintain, on a consolidated basis, during the fiscal year ending December 31,
2005, their Debt Service Coverage Ratio, determined as at the end of such fiscal
year, at not less than 1.05 to 1.00.

- 4 -

Medtox - Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------

 

        “Section 6.14 Minimum Pre-Tax Net Income. The Borrowers will achieve, on
a consolidated basis, during each year-to-date period described below, Pre-Tax
Net Income of not less than the amount set forth opposite such date:

Date Minimum Pre-Tax Net Income    June 30, 2005     $ 650,000   September 30,
2005   $ 1,650,000    December 31, 2005   $ 2,000,000  

 

        “Section 7.10 Capital Expenditures. During each fiscal year-to-date
period described below, the Borrowers and their Subsidiaries will not incur or
contract to incur in the aggregate, Capital Expenditures of more than the amount
set forth opposite such period:

Year-to-date period ending Capital Expenditures   June 30, 2005     $ 4,000,000
  September 30, 2005   $ 4,500,000   December 31, 2005   $ 4,500,000  

    8.        Changes to Exhibits. Exhibit B to the Credit Agreement is replaced
by Exhibit B to this Amendment.

    9.        No Other Changes. Except as explicitly amended by this Amendment,
all of the terms and conditions of the Credit Agreement shall remain in full
force and effect and shall apply to any advance or letter of credit thereunder.

    10.        Conditions Precedent. This Amendment shall be effective when the
Lender shall have received an executed original hereof, together with each of
the following, each in substance and form acceptable to the Lender in its sole
discretion:

    (a)        The 2005 Capex Note, duly executed on behalf of the Borrowers.

    (b)        A Certificate of the Secretary of each Borrower certifying as to
(i) the resolutions of its board of directors approving the execution and
delivery of this Amendment, (ii) the fact that its articles of incorporation and
bylaws, which were certified and delivered to the Lender continue in full force
and effect and have not been amended or otherwise modified except as set forth
in the Certificate to be delivered, and (iii) that its officers and agents who
have been certified to the Lender, as being authorized to sign and to act on its
behalf continue to be so authorized or setting forth the sample signatures of
each of its officers and agents authorized to execute and deliver this Amendment
and all other documents, agreements and certificates on its behalf.

- 5 -

Medtox - Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------

    11.        Representations and Warranties. Each Borrower hereby represents
and warrants to the Lender as follows:

    (a)        Each Borrower has all requisite power and authority to execute
this Amendment and to perform all of its obligations hereunder, and this
Amendment has been duly executed and delivered by the Borrower and constitutes
the legal, valid and binding obligation of each Borrower, enforceable in
accordance with its terms.

    (b)        The execution, delivery and performance by each Borrower of this
Amendment have been duly authorized by all necessary corporate action and do not
(i) require any authorization, consent or approval by any governmental
department, commission, board, bureau, agency or instrumentality, domestic or
foreign, (ii) violate any provision of any law, rule or regulation or of any
order, writ, injunction or decree presently in effect, having applicability to
any Borrower, or the articles of incorporation or by-laws of any Borrower, or
(iii) result in a breach of or constitute a default under any indenture or loan
or credit agreement or any other agreement, lease or instrument to which any
Borrower is a party or by which it or its properties may be bound or affected.

    (c)        All of the representations and warranties contained in Article V
of the Credit Agreement are correct on and as of the date hereof as though made
on and as of such date, except to the extent that such representations and
warranties relate solely to an earlier date.

    12.        No Waiver. The execution of this Amendment and acceptance of any
documents related hereto shall not be deemed to be a waiver of any Default or
Event of Default under the Credit Agreement or breach, default or event of
default under any Security Document or other document held by the Lender,
whether or not known to the Lender and whether or not existing on the date of
this Amendment.

    13.        Release. Each Borrower hereby absolutely and unconditionally
releases and forever discharges the Lender, and any and all participants, parent
corporations, subsidiary corporations, affiliated corporations, insurers,
indemnitors, successors and assigns thereof, together with all of the present
and former directors, officers, agents and employees of any of the foregoing,
from any and all claims, demands or causes of action of any kind, nature or
description, whether arising in law or equity or upon contract or tort or under
any state or federal law or otherwise, which any Borrower has had, now has or
has made claim to have against any such person for or by reason of any act,
omission, matter, cause or thing whatsoever arising from the beginning of time
to and including the date of this Amendment, whether such claims, demands and
causes of action are matured or unmatured or known or unknown.

- 6 -

Medtox - Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------

    14.        Costs and Expenses. The Borrowers hereby reaffirm their agreement
under the Credit Agreement to pay or reimburse the Lender on demand for all
costs and expenses incurred by the Lender in connection with the Loan Documents,
including without limitation all reasonable fees and disbursements of legal
counsel. Without limiting the generality of the foregoing, the Borrowers
specifically agree to pay all fees and disbursements of counsel to the Lender
for the services performed by such counsel in connection with the preparation of
this Amendment and the documents and instruments incidental hereto. The
Borrowers hereby agree that the Lender may, at any time or from time to time in
its sole discretion and without further authorization by the Borrowers, make a
loan to the Borrowers under the Credit Agreement, or apply the proceeds of any
loan, for the purpose of paying any such fees, disbursements, costs and
expenses.

    15.        Miscellaneous. This Amendment may be executed in any number of
counterparts, each of which when so executed and delivered shall be deemed an
original and all of which counterparts, taken together, shall constitute one and
the same instrument.

- 7 -

Medtox - Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------

        IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed as of the date first written above.

WELLS FARGO BUSINESS CREDIT, INC MEDTOX SCIENTIFIC, INC.   MEDTOX DIAGNOSTICS,
INC   MEDTOX LABORATORIES, INC   CONSOLIDATED MEDICAL SERVICES, INC By /s/
Kimberly Leppanen                               Kimberly Leppanen       Its Vice
President By /s/ Richard J. Braun                                      
      Richard J. Braun         Their Chief Executive Officer

[Signature Page to Sixth Amendment to MEDTOX Credit Agreement]

--------------------------------------------------------------------------------

Exhibit A to Sixth Amendment to
Amended and Restated Credit and Security Agreement

2005 CAPEX NOTE

$1,500,000

Minneapolis, Minnesota
June 27, 2005

        For value received, the undersigned, MEDTOX SCIENTIFIC, INC., a Delaware
corporation, MEDTOX LABORATORIES, INC., a Delaware corporation, MEDTOX
DIAGNOSTICS, INC., a Delaware corporation, and CONSOLIDATED MEDICAL SERVICES,
INC., a Delaware corporation (together, the “Borrowers”), hereby jointly and
severally promise to pay as provided in the Credit Agreement (defined below), to
the order of WELLS FARGO BUSINESS CREDIT, INC., a Minnesota corporation (the
“Lender”), at its main office in Minneapolis, Minnesota, or at any other place
designated at any time by the holder hereof, in lawful money of the United
States of America and in immediately available funds, the principal sum of One
Million Five Hundred Thousand Dollars ($1,500,000) or, if less, the aggregate
unpaid principal amount of all 2004 Capex Advances made by the Lender to the
Borrowers under the Credit Agreement together with interest on the principal
amount hereunder remaining unpaid from time to time, computed on the basis of
the actual number of days elapsed and a 360-day year, from the date hereof until
this Note is fully paid at the rate from time to time in effect under the
Amended and Restated Credit and Security Agreement dated as of May 7, 2001 but
effective as of March 31, 2001(as amended to date and as the same may hereafter
be amended, supplemented or restated from time to time, the “Credit Agreement”)
by and among the Lender and the Borrowers. The principal hereof and interest
accruing thereon shall be due and payable as provided in the Credit Agreement.
This Note may be prepaid only in accordance with the Credit Agreement.

        This Note is issued pursuant, and is subject, to the Credit Agreement,
which provides, among other things, for acceleration hereof. This Note is the
2005 Capex Note referred to in the Credit Agreement. This Note is secured, among
other things, pursuant to the Credit Agreement and the Security Documents as
therein defined, and may now or hereafter be secured by one or more other
security agreements, mortgages, deeds of trust, assignments or other instruments
or agreements.

        The Borrowers hereby jointly and severally agree to pay all costs of
collection, including attorneys’ fees and legal expenses in the event this Note
is not paid when due, whether or not legal proceedings are commenced.

        Presentment or other demand for payment, notice of dishonor and protest
are expressly waived.

- 1 -

Exhibit A to MEDTOX Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------

  MEDTOX SCIENTIFIC, INC.   MEDTOX DIAGNOSTICS, INC   MEDTOX LABORATORIES, INC  
CONSOLIDATED MEDICAL SERVICES, INC                                           By
/s/ Richard J. Braun                                             Richard J.
Braun         Their Chief Executive Officer

- 2 -

Exhibit A to MEDTOX Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------

Exhibit B to Sixth Amendment to Amended
and Restated Credit and Security Agreement

COMPLIANCE CERTIFICATE

To: Kimberly Leppanen   Wells Fargo Business Credit, Inc.     Date:
__________________     Subject: MEDTOX Scientific, Inc.   MEDTOX Laboratories,
Inc.   MEDTOX Diagnostics, Inc.   Consolidated Medical Services, Inc.    

        Financial Statements

        In accordance with our Amended and Restated Credit and Security
Agreement dated as of May 7, 2001, but effective as of March 31, 2001(as amended
to date, the “Credit Agreement”), attached are the financial statements of
MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc.,
and Consolidated Medical Services, Inc. (together, the “Borrowers”) as of and
for ________________ (the “Reporting Date”) and the year-to-date period then
ended (the “Current Financials”). All terms used in this certificate have the
meanings given in the Credit Agreement.

        I certify that the Current Financials have been prepared in accordance
with GAAP, subject to year-end audit adjustments, and fairly present the
Borrowers’ financial condition and the results of its operations as of the date
thereof.

          Events of Default. (Check one):

  |_|

The undersigned does not have knowledge of the occurrence of a Default or Event
of Default under the Credit Agreement not previously reported to the Lender.

  |_|

The undersigned has knowledge of the occurrence of a Default or Event of Default
under the Credit Agreement and attached hereto is a statement of the facts with
respect thereto.

- 1 -

Exhibit B to MEDTOX Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------

          Financial Covenants. I further hereby certify as follows:

1.        Minimum Debt Service Coverage Ratio. Pursuant to Section 6.13 of the
Credit Agreement, as of the Reporting Date, the Borrowers’ Debt Service Coverage
Ratio was _____ to 1.00 which |_| satisfies |_| does not satisfy the requirement
that such ratio be no less than 1.10 to 1.00 for fiscal year 2005.

2.        Minimum Pre-Tax Net Income. Pursuant to Section 6.14 of the Credit
Agreement, the Borrowers’ Pre-Tax Net Income for the period ending on the
Reporting Date, was $____________, which |_| satisfies |_| does not satisfy the
requirement that such amount be not less than $_____________ for such period as
set forth in table below:

Date Minimum Pre-Tax Net Income June 30, 2005 $   650,000 September 30, 2005
$1,650,000 December 31, 2005 $2,000,000

3.        Capital Expenditures. Pursuant to Section 7.10 of the Credit
Agreement, for the year-to-date period ending on the Reporting Date, the
Borrowers have expended or contracted to expend for Capital Expenditures,
$__________________ in the aggregate which |_| satisfies |_| does not satisfy
the requirement that such expenditures not exceed $_____________ in the
aggregate during such period as set forth below:

Year-to-date period ending Capital Expenditures June 30, 2005 $4,000,000
September 30, 2005 $4,500,000 December 31, 2005 $4,500,000

4.        Salaries. As of the Reporting Date, the Borrowers |_| are |_| are not
in compliance with Section 7.17 of the Credit Agreement concerning salaries.

        Attached hereto are all relevant facts in reasonable detail to evidence,
and the computations of the financial covenants referred to above. These
computations were made in accordance with GAAP.

- 2 -

Exhibit B to MEDTOX Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------

  MEDTOX SCIENTIFIC, INC.   MEDTOX LABORATORIES, INC   MEDTOX DIAGNOSTICS, INC  
CONSOLIDATED MEDICAL SERVICES, INC               By /s/ Richard J.
Braun                                             Richard J. Braun         Their
Chief Executive Officer

- 3 -

Exhibit B to MEDTOX Sixth Amendment to Credit Agreement

--------------------------------------------------------------------------------